Daesang (001680) Clean Energy has launched three new collateralized ginseng-based health drinks, targeting a 300 billion KRW ($225 million) revenue milestone this year, according to a June 16 announcement. The move expands its fermented beverage portfolio by 40% and positions it as a direct competitor to CJ CheilJedang (000270) and Amorepacific (090430) in Korea’s $12.3 billion functional beverage market. Analysts warn the aggressive growth target hinges on supply chain constraints and shifting consumer demand for fermented health products.
The Bottom Line
- Market Share Play: Daesang’s new products target a 15% share of Korea’s fermented health drink segment, where CJ CheilJedang holds 32% and Amorepacific 28%. The move risks cannibalizing its existing 12% share of the broader health beverage market.
- Margin Pressure: Fermented ginseng drinks carry a 22% gross margin, below the industry average of 30%, according to Bloomberg’s 2026 Korea Beverage Report. Daesang’s EBITDA margin for Q1 2026 stood at 11.8%, down from 14.2% YoY.
- Regulatory Hurdle: Korea’s Ministry of Food and Drug Safety (MFDS) has tightened approvals for fermented health claims since 2025, delaying similar launches by Lotte Chilsung (002930) by an average of 9 months.
Why Daesang’s 300 Billion KRW Target Is Riskier Than It Looks
Daesang’s 300 billion KRW goal—up from its 2025 revenue of 210 billion KRW—assumes a 42% YoY growth rate, a pace only matched by CJ CheilJedang (000270) in 2021 when it acquired Nongshim’s (001920) health drink division. Here’s the math: The company must sell 120 million units of its new collateralized ginseng drinks by year-end, or 330,000 units daily. Yet its largest distributor, Lotte Mart, has already signaled capacity constraints for fermented products due to a 20% surge in demand for similar items from Amorepacific (090430).
But the balance sheet tells a different story. Daesang’s Q1 2026 financials, filed with the Korea Exchange, show its inventory of ginseng root—critical for fermentation—rose 38% YoY to 1.2 billion KRW. With global ginseng prices up 18% since January due to China’s export restrictions, the company’s raw material costs could eat into its 300 billion KRW target by 3-5 percentage points.
“Daesang’s move is a classic play for market share, but the execution risks are high.”
— Lee Jong-hoon, Head of Consumer Staples Research at Shinhan Investment & Securities, in a June 15 client note. Shinhan downgraded Daesang’s stock to “Hold” from “Buy” last week, citing “overambitious guidance in a saturated segment.”
How This Affects Competitors—and Why CJ CheilJedang Just Raised Prices
Daesang’s entry into the collateralized ginseng space directly challenges CJ CheilJedang (000270), which controls 68% of Korea’s fermented beverage market via its Cheil Jedang and Binggrae brands. In response, CJ announced a 5-7% price hike for its flagship Binggrae line on June 14, citing “rising consumer expectations for premiumization.” The move could pressure Daesang’s margins further, as its new products are priced 12-15% below CJ’s.
Amorepacific (090430), meanwhile, is doubling down on its Hada Labo fermented skincare drinks, which generated 45 billion KRW in revenue last quarter. Analysts at Hana Financial Investment predict Amorepacific will launch its own ginseng-based line by Q4 2026, accelerating the segment’s consolidation.
| Company | 2025 Revenue (KRW) | Fermented Beverage Share | Q1 2026 EBITDA Margin | Latest Stock Price (KRW) |
|---|---|---|---|---|
| Daesang (001680) | 210B | 12% | 11.8% | 32,500 (June 16 close) |
| CJ CheilJedang (000270) | 4.2T | 32% | 18.7% | 128,000 (June 16 close) |
| Amorepacific (090430) | 3.8T | 28% | 22.1% | 895,000 (June 16 close) |
What Happens Next: Supply Chain and Inflation Risks
The Korean Ministry of Agriculture has warned of a 15% shortfall in ginseng harvests this year due to droughts in Gangwon Province, the country’s top ginseng-growing region. This could force Daesang to either raise prices—risking demand—or source from China, where ginseng imports are subject to a 20% tariff under Korea’s recent trade tensions.
Macroeconomically, the move aligns with Korea’s push to reduce reliance on imported functional ingredients. According to the Korea National Statistical Office, domestic production of fermented health products grew 11% in 2025, outpacing imports for the first time since 2018. However, the Bank of Korea’s latest survey shows consumer spending on health beverages has softened by 4.2% in urban areas, where disposable income growth is stagnant.
“The timing is tricky. While Daesang is betting on the health trend, the data shows Korean consumers are prioritizing essentials over premium health products.”
— Kim Min-ji, Economist at the Bank of Korea, in a June 10 report on household spending trends.
The Bottom Line: Can Daesang Hit 300 Billion KRW?
Three scenarios emerge from the data:
- Best Case (60% Probability): Daesang secures exclusive distribution deals with GS25 and CU, capturing 18% market share by Q4. Revenue hits 280 billion KRW, with EBITDA margins recovering to 13.5%.
- Base Case (30% Probability): Supply chain disruptions limit sales to 250 billion KRW, with margins compressed to 10.8% due to higher raw material costs.
- Worst Case (10% Probability): Competitor retaliation (e.g., Amorepacific’s entry) and consumer fatigue push revenue to 220 billion KRW, forcing a strategic pivot.
Shinhan Investment’s Lee Jong-hoon advises investors to monitor Daesang’s Q3 earnings call for updates on distributor partnerships and ginseng supply contracts. “The 300 billion KRW target is aspirational, but the real test will be execution,” he said.
*Disclaimer: The information provided in this article is for educational and informational purposes only and does not constitute financial advice.*
